La Fenice<sup>®</sup> Insulin Pump Awarded Re-registration Certificate

Shanghai, China – 12 January, 2015 - MicroPort Lifesciences (Beijing) Co ("MicroPort Lifesciences"), a subsidiary of Shanghai MicroPort Medical (Group) Co, recently obtained a re-registration certificate from China Food and Drug Administration for La Fenice® Insulin Pump ("La Fenice®"), adding vibration alarming function to the original design.
 
La Fenice® is a medical device in-house developed by MicroPort Lifesciences. It is used for the administration of insulin in the treatment of diabetes mellitus. It mimics nature pancreatic insulin delivery by infusing fast acting insulin continuously through infusion set and reservoir to maintain stable blood glucose for the patient throughout the day and night. The pump delivers rapid-acting insulin in two ways - a basal dose pumped continuously at an adjustable basal rate to deliver insulin needed between meals and at night, and a bolus dose pumped to cover food eaten or to correct a high blood glucose level.
 
La Fenice® offers two models: Model A with four different bolus modes in larger doses to cover a meal or to correct for hyperglycemia bolus and Model E in which automatically allocated basal rate of insulin is delivered around the clock.
 
La Fenice® is specially designed for Chinese patients, based on their eating habits and lifestyle. Compared to other insulin pumps, La Fenice® can more effectively control blood glucose, improving patients' quality of life.
 
According to statistics, China has the highest growth rate of diabetes patients in the world, with one in 10 people suffering from diabetes.